Correlation of miR-31 and miR-373 expression with KRAS mutations and its impact on prognosis in colorectal cancer

Introduction: Colorectal cancers (CRC) are among the most common cancers. There are different modalities for treatment including chemotherapy, surgery, and radiotherapy. There are some mutations in cancers which can assist in the treatment and better prognosis of patients. In this study, two molecular markers (miR-31 and miR-373) were involved in the pathogenesis of CRC and their association with histopathological features was investigated. As well, the prognostic value of these molecular markers was investigated in CRC patients with or without common KRAS mutations. Methods: Paraffin blocks of tissue samples from 150 patients who underwent colon surgery between 2018 and 2020 were prepared by the Pathology Department of Imam Hossein Hospital (Tehran, Iran). After DNA and RNA isolation, gene expression of miR-31 and miR-373 was determined using probe-based quantitative real-time polymerase chain reaction (qRT-PCR). Mutations of KRAS were surveyed using conventional PCR and agarose gel electrophoresis. Results: The mean age of the patients was 57.2 +/- 13.4 years. KRAS codon 12 and 13 mutations were positive in 31 (20.6%) and 22 (14.6%) cases, respectively. The results showed that KRAS common mutations occurred in 32.6% of Iranian CRC patients. The expression levels of miR-31 and miR-373 increased in CRC patients with KRAS mutations in comparison with patients without these mutations. Conclusion: Considering the role of miR-31 and miR-373 in CRC tumor progression, it seems that the CRC patients bearing KRAS mutations have a poorer prognosis respective to patients without KRAS mutations.